Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.77 |
| ▸ | ITGAV | P06756 | 19/20 | 0.77 |
| ▸ | ITGB1 | P05556 | 18/20 | 0.77 |
| ▸ | ITGA5 | P08648 | 18/20 | 0.77 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4741813 | 0.93 | ITGB3 (0.79) | ITGB3ITGAVITGB1ITGA5ITGA2B | |
| SCHEMBL4743165 | 0.90 | ITGB3 (0.78) | ITGB3ITGAVITGB1ITGA5 | |
| SCHEMBL4785445 | 0.89 | ITGB3 (0.71) | ITGB3ITGAVITGB1ITGA5ITGA2B | |
| SCHEMBL13908271 | 0.88 | ITGB3 (0.82) | ITGB3ITGAVITGB1ITGA5 | |
| SCHEMBL4743171 | 0.88 | ITGB3 (0.75) | ITGB3ITGAVITGB1ITGA5 | |
| SCHEMBL14270769 | 0.87 | ITGB3 (1.00) | ITGB3ITGAVITGB1ITGA5 | |
| SCHEMBL4741275 | 0.86 | ITGB3 (0.73) | ITGB3ITGAVITGB1ITGA5 | |
| SCHEMBL4739780 | 0.86 | ITGB3 (0.69) | ITGB3ITGAVITGB1ITGA5 | |
| SCHEMBL4742898 | 0.86 | ITGB3 (0.78) | ITGB3ITGAVITGB1ITGA5 | |
| SCHEMBL4742645 | 0.85 | ITGB3 (0.77) | ITGB3ITGAVITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008093064-A1 | L-ALANINE DERIVATIVES AS α5 BETA 1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | WO | claimed |
| US-20080182842-A1 | L-alanine derivatives as a5beta1 antagonists | ASTRAZENECA AB (SE) | 2008-07-31 | — | — | US | claimed |
| WO-2008093064-A1 | L-ALANINE DERIVATIVES AS α5 BETA 1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | WO | disclosed |
| US-20080182842-A1 | L-alanine derivatives as a5beta1 antagonists | ASTRAZENECA AB (SE) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182842-A1 | L-alanine derivatives as a5beta1 antagonists | ITGB1, ITGA2B, ITGB5 | ITGB3 10/4885ITGAV 7/4885ITGB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.